BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 17001889)

  • 1. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
    Aron M; Kapila K; Verma K
    Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
    Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
    Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
    Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
    Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
    Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
    Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galectin-3 is not useful in thyroid FNA.
    Mills LJ; Poller DN; Yiangou C
    Cytopathology; 2005 Jun; 16(3):132-8. PubMed ID: 15924608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.
    Xu XC; el-Naggar AK; Lotan R
    Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.
    Fernández PL; Merino MJ; Gómez M; Campo E; Medina T; Castronovo V; Sanjuán X; Cardesa A; Liu FT; Sobel ME
    J Pathol; 1997 Jan; 181(1):80-6. PubMed ID: 9072007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
    Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
    Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions.
    Kim MJ; Kim HJ; Hong SJ; Shong YK; Gong G
    Acta Cytol; 2006; 50(1):28-34. PubMed ID: 16514837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.
    Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J
    Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 is a presurgical marker of human thyroid carcinoma.
    Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A
    Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM; Ibrahim TR
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions.
    Matesa N; Samija I; Kusić Z
    Cytopathology; 2007 Apr; 18(2):112-6. PubMed ID: 17397496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
    de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
    Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 immunodetection may improve cytological diagnosis of occult papillary thyroid carcinoma.
    Pisani T; Vecchione A; Giovagnolii MR
    Anticancer Res; 2004; 24(2C):1111-2. PubMed ID: 15154632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
    Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
    Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.